NCNA NuCana plc

2.73
-0.03  -1%
Previous Close 2.76
Open 2.76
52 Week Low 2.64
52 Week High 7.83
Market Cap $142,402,260
Shares 52,162,000
Float 52,162,000
Enterprise Value $34,667,013
Volume 471,855
Av. Daily Volume 617,052
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
NUC-7738 (NuTide:701)
Solid tumors
Phase 1
Phase 1
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
NUC-3373 (NuTide:302)
Colorectal Cancer
Phase 1b
Phase 1b
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
NUC-3373 (NuTide:301)
Solid tumors
Phase 1
Phase 1
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
NUC-1031 (NuTide:121)
Front-Line Treatment of Advanced Biliary Tract Cancer
Phase 3
Phase 3
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Drug Pipeline

Drug Stage Notes
NUC-1031 (Acelarin)
Platinum-sensitive ovarian cancer
Phase 2
Phase 2
Part 2 portion of trial will not be initiated.
NUC-1031 (Acelarin)
Pancreatic cancer
Phase 3
Phase 3
Phase 3 enrolment suspended due to futility - August 20, 2019.

Latest News

  1. EDINBURGH, United Kingdom, May 25, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies Virtual Healthcare Conference being held from June 1 to June 4, 2021.

    Event: Jefferies Virtual Healthcare Conference
    Date: Tuesday, June 1, 2021
    Time: 9:30 AM ET

    The presentation will be webcast live and available for replay under "Events & Presentations" in the Investors section of the Company's website at www.nucana.com.

    About NuCana

    NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our ProTide…

    EDINBURGH, United Kingdom, May 25, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies Virtual Healthcare Conference being held from June 1 to June 4, 2021.

    Event: Jefferies Virtual Healthcare Conference

    Date: Tuesday, June 1, 2021

    Time: 9:30 AM ET

    The presentation will be webcast live and available for replay under "Events & Presentations" in the Investors section of the Company's website at www.nucana.com.

    About NuCana

    NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. NuCana's robust pipeline includes three ProTides in clinical development. Acelarin and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents. Acelarin is in a Phase III study for patients with advanced biliary tract cancer. NUC-3373 is in a Phase I study for the potential treatment of a wide range of patients with advanced solid tumors and a Phase Ib study for patients with metastatic colorectal cancer. Our third ProTide, NUC-7738, is a transformation of a novel nucleoside analog (3'-deoxyadenosine) and is in a Phase I study for patients with advanced solid tumors.

    Forward-Looking Statements

    This press release may contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the "Company"). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning the Company's planned and ongoing clinical studies for the Company's product candidates and the potential advantages of those product candidates, including Acelarin, NUC-3373 and NUC-7738; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies; the Company's goals with respect to the development, regulatory pathway and potential use, if approved, of each of its product candidates; and the utility of prior non-clinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of the Company's Annual Report on Form 20-F for the year ended December 31, 2020 filed with the Securities and Exchange Commission ("SEC") on March 4, 2021, and subsequent reports that the Company files with the SEC. Forward-looking statements represent the Company's beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward-looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.

    For more information, please contact:

    Hugh S. Griffith

    Chief Executive Officer

    NuCana plc

    Tel: +44 131 357 1111

    Westwicke, an ICR Company

    Chris Brinzey

    Tel: +1 339-970-2843

    RooneyPartners

    Marion Janic

    Tel: +1 212-223-4017



    View Full Article Hide Full Article
  2. Presented Encouraging Clinical Data at ASCO-GI and AACR

    Additional Clinical Data Announcements and Study Initiations Expected in 2021

    EDINBURGH, United Kingdom, May 19, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced financial results for the first quarter ended March 31, 2021 and provided an update on its broad clinical program with its transformative ProTide therapeutics.

    As of March 31, 2021, NuCana had cash and cash equivalents of £78.6 million compared to £87.4 million as of December 31, 2020. NuCana continues to advance its various clinical programs and reported a net loss of £9.8 million for the quarter ended March 31, 2021, as compared to a loss of £4.0 million for the quarter ended March 31, 2020. Basic and diluted…

    Presented Encouraging Clinical Data at ASCO-GI and AACR

    Additional Clinical Data Announcements and Study Initiations Expected in 2021

    EDINBURGH, United Kingdom, May 19, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced financial results for the first quarter ended March 31, 2021 and provided an update on its broad clinical program with its transformative ProTide therapeutics.

    As of March 31, 2021, NuCana had cash and cash equivalents of £78.6 million compared to £87.4 million as of December 31, 2020. NuCana continues to advance its various clinical programs and reported a net loss of £9.8 million for the quarter ended March 31, 2021, as compared to a loss of £4.0 million for the quarter ended March 31, 2020. Basic and diluted loss per share was £0.19 for the quarter ended March 31, 2021, as compared to £0.12 per share for quarter ended March 31, 2020.

    "We are very pleased with our momentum in 2021," said Hugh S. Griffith, NuCana's Founder and Chief Executive Officer. "In January, we presented data at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) from the NuTide:302 study demonstrating NUC-3373's encouraging efficacy signals and favorable safety profile in patients with advanced colorectal cancer. Among the efficacy-evaluable population, a disease control rate of 62% was achieved. In addition, NUC-3373 was well tolerated with no hand-foot syndrome or neutropenia as well as lower rates of diarrhea, mucositis and stomatitis as compared to historical data for 5-FU and capecitabine in the frontline treatment of patients with colorectal cancer."

    Mr. Griffith continued: "In April, we were excited to present five posters at the American Association for Cancer Research (AACR) Annual Meeting. NUC-3373 maintained the encouraging 62% disease control rate in the efficacy-evaluable population in the NuTide:302 study. The poster also detailed three patients who experienced reductions in their target lesions of 40%, 28% and 15% and several patients who achieved a longer progression-free survival on NUC-3373 than they had on their prior therapy. We also presented additional clinical data from the ongoing Phase I study of NUC-7738. These data demonstrated NUC-7738's encouraging anti-cancer activity and favorable tolerability profile. Three case studies described patients who achieved tumor volume reductions and prolonged stable disease on NUC-7738. Other AACR posters showed NUC-3373-treated colon cancer cells are able to activate a natural killer cell response and described how NUC-7738 was designed to overcome the key cancer resistance mechanisms which have prevented the clinical development of its parent nucleoside analog, 3'-deoxyadenosine. Overall, these presentations highlighted the potential of our ProTides to significantly improve the treatment outcomes for patients with cancer."

    Mr. Griffith concluded: "We are excited with the progress we have made so far in 2021. We remain focused on continuing to drive recruitment across all of our ongoing studies, including our Phase III study of Acelarin plus cisplatin in patients with biliary tract cancer as well as initiating new studies, including our second Phase III study evaluating NUC-3373 in combination with other agents for patients with colorectal cancer. We look forward to providing additional updates as we go through 2021."

    Anticipated 2021 Milestones

    • Acelarin is a ProTide transformation of gemcitabine. In 2021, NuCana expects to:

      • Complete recruitment sufficient to enable the first interim analysis in 2022 of the Phase III study of Acelarin combined with cisplatin as a first-line treatment for patients with advanced biliary tract cancer.



    • NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-FU. In 2021, NuCana expects to:

      • Report data from the Phase Ib study (NuTide:302) of NUC-3373 in combination with other agents with which 5-FU is typically combined, such as leucovorin, oxaliplatin and irinotecan in patients with advanced colorectal cancer;

      • Initiate and report data from a Phase Ib expansion / Phase II study of NUC-3373 in combination with other agents for patients with colorectal cancer;
      • Initiate a Phase III study of NUC-3373 in combination with other agents for patients with colorectal cancer; and
      • Report data from the Phase I study (NuTide:301) of NUC-3373 in patients with advanced solid tumors.



    • NUC-7738 is a ProTide transformation of a novel nucleoside analog, 3'-deoxyadenosine. In 2021, NuCana expects to:

      • Report data from the Phase I study (NuTide:701) of NUC-7738 in patients with advanced solid tumors; and

      • Initiate a Phase II study of NUC-7738 in patients with solid tumors.

    About NuCana

    NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. NuCana's robust pipeline includes three ProTides in clinical development. Acelarin and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents. Acelarin is in a Phase III study for patients with advanced biliary tract cancer. NUC-3373 is in a Phase I study for the potential treatment of a wide range of patients with advanced solid tumors and a Phase Ib study for patients with metastatic colorectal cancer. Our third ProTide, NUC-7738, is a transformation of a novel nucleoside analog (3'-deoxyadenosine) and is in a Phase I study for patients with advanced solid tumors.

    Forward-Looking Statements

    This press release may contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the "Company"). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning the Company's planned and ongoing clinical studies for the Company's product candidates and the potential advantages of those product candidates, including Acelarin, NUC-3373 and NUC-7738; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies; the Company's goals with respect to the development, regulatory pathway and potential use, if approved, of each of its product candidates; and the utility of prior non-clinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of the Company's Annual Report on Form 20-F for the year ended December 31, 2020 filed with the Securities and Exchange Commission ("SEC") on March 4, 2021, and subsequent reports that the Company files with the SEC. Forward-looking statements represent the Company's beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward-looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.



    Unaudited Condensed Consolidated Statements of Operations

      For the Three Months Ended

    March 31,

      2021

     2020

         
      (in thousands, except per share data)
      £ £
    Research and development expenses (8,706) (5,938)
    Administrative expenses (2,104) (1,609)
    Net foreign exchange (losses) gains (677) 2,127
         
    Operating loss (11,487) (5,420)
    Finance income 24 144
         
    Loss before tax (11,463) (5,276)
    Income tax credit 1,702 1,310
         
    Loss for the period (9,761) (3,966)
         
    Basic and diluted loss per share (0.19) (0.12)



    Unaudited Condensed Consolidated Statements of Financial Position

      March 31, 2021

     December 31, 2020

         
      (in thousands)
      £ £
    Assets    
    Non-current assets    
    Intangible assets 4,764 4,753
    Property, plant and equipment 1,098 1,189
    Deferred tax asset 40 44
      5,902 5,986
    Current assets    
    Prepayments, accrued income and other receivables 4,813 4,628
    Current income tax receivable 11,529 9,822
    Cash and cash equivalents 78,625 87,356
         
      94,967 101,806
    Total assets 100,869 107,792
         
    Equity and liabilities    
    Capital and reserves    
    Share capital and share premium 143,135 142,937
    Other reserves 67,470 66,887
    Accumulated deficit (119,146) (110,594)
    Total equity attributable to equity holders of the Company 91,459 99,230
         
    Non-current liabilities    
    Provisions 46 46
    Lease liabilities 296 367
      342 413
         
    Current liabilities    
    Trade payables 3,542 2,257
    Payroll taxes and social security 159 177
    Accrued expenditure 5,087 5,437
    Lease liabilities 280 278
      9,068 8,149
    Total liabilities 9,410 8,562
    Total equity and liabilities 100,869 107,792



    Unaudited Condensed Consolidated Statements of Cash Flows

      For the Three Months Ended

    March 31,
      2021

     2020

         
      (in thousands)
      £ £
    Cash flows from operating activities    
    Loss for the period (9,761) (3,966)
    Adjustments for:    
    Income tax credit (1,702) (1,310)
    Amortization and depreciation 222 217
    Finance income (24) (144)
    Interest expense on lease liabilities 6 -
    Share-based payments 1,795 856
    Net foreign exchange losses (gains) 664 (2,164)
      (8,800) (6,511)
    Movements in working capital:    
    (Increase) decrease in prepayments, accrued income and other receivables (191) 423
    Increase in trade payables 1,285 44
    Decrease in payroll taxes, social security and accrued expenditure (368) (165)
    Movements in working capital 726 302
    Cash used in operations (8,074) (6,209)
    Net income tax received - -
    Net cash used in operating activities (8,074) (6,209)
    Cash flows from investing activities    
    Interest received 24 187
    Payments for property, plant and equipment (4) (10)
    Payments for intangible assets (138) (398)
    Net cash used in investing activities (118) (221)
    Cash flows from financing activities    
    Payments for lease liabilities (74) (73)
    Proceeds from issue of share capital 198 -
    Net cash from (used in) financing activities 124 (73)
    Net decrease in cash and cash equivalents (8,068) (6,503)
    Cash and cash equivalents at beginning of period 87,356 51,962
    Effect of exchange rate changes on cash and cash equivalents (663) 2,141
    Cash and cash equivalents at end of period 78,625 47,600



    For more information, please contact:

    NuCana plc

    Hugh S. Griffith

    Chief Executive Officer

    +44 131 357 1111

    Westwicke, an ICR Company

    Chris Brinzey

    +1 339-970-2843

    RooneyPartners

    Marion Janic

    +1 212-223-4017

    m



    View Full Article Hide Full Article
  3. EDINBURGH, United Kingdom, April 28, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will host one-on-one meetings at the 7th Annual Truist Securities Life Sciences Summit being held virtually from May 4 to May 5, 2021.

    Event: 7th Annual Truist Securities Life Sciences Summit
    Date: May 4 to May 5, 2021

    About NuCana

    NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional…

    EDINBURGH, United Kingdom, April 28, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will host one-on-one meetings at the 7th Annual Truist Securities Life Sciences Summit being held virtually from May 4 to May 5, 2021.

    Event: 7th Annual Truist Securities Life Sciences Summit

    Date: May 4 to May 5, 2021

    About NuCana

    NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. NuCana's robust pipeline includes three ProTides in clinical development. Acelarin and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents. Acelarin is in a Phase III study for patients with advanced biliary tract cancer and a Phase III study for patients with metastatic pancreatic cancer for which enrollment has been suspended. NUC-3373 is in a Phase I study for the potential treatment of a wide range of patients with advanced solid tumors and a Phase Ib study for patients with metastatic colorectal cancer. Our third ProTide, NUC-7738, is a transformation of a novel nucleoside analog (3'-deoxyadenosine) and is in a Phase I study for patients with advanced solid tumors.

    Forward-Looking Statements

    This press release may contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the "Company"). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning the Company's planned and ongoing clinical studies for the Company's product candidates and the potential advantages of those product candidates, including Acelarin, NUC-3373 and NUC-7738; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies; the Company's goals with respect to the development, regulatory pathway and potential use, if approved, of each of its product candidates; and the utility of prior non-clinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of the Company's Annual Report on Form 20-F for the year ended December 31, 2020 filed with the Securities and Exchange Commission ("SEC") on March 4, 2021, and subsequent reports that the Company files with the SEC. Forward-looking statements represent the Company's beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward-looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.

    For more information, please contact:

    Hugh S. Griffith

    Chief Executive Officer

    NuCana plc

    Tel: +44 131 357 1111

    Westwicke, an ICR Company

    Chris Brinzey

    Tel: +1 339-970-2843

    RooneyPartners

    Marion Janic

    Tel: +1 212-223-4017



    View Full Article Hide Full Article
    • NUC-3373 Shows Encouraging Efficacy Signals and a Favorable Safety Profile in Patients with Advanced Colorectal Cancer
    • NUC-3373 Promotes Natural Killer Cell Activation by Colorectal Cancer Cells

    • NUC-7738 Demonstrates Anti-Cancer Activity, Prolonged Stable Disease and a Favorable Tolerability Profile in Patients with Advanced Solid Tumors

    • NUC-7738 Generates High and Prolonged Intracellular Levels of the Active Anti-Cancer Metabolite 3'-dATP

    • Acelarin Induces Persistent DNA Damage in Biliary Tract Cancer Cells

    EDINBURGH, United Kingdom, April 10, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced the presentation of five posters at the American Association for Cancer Research (AACR) Annual Meeting 2021 being held virtually April 9 to 14…

    • NUC-3373 Shows Encouraging Efficacy Signals and a Favorable Safety Profile in Patients with Advanced Colorectal Cancer
    • NUC-3373 Promotes Natural Killer Cell Activation by Colorectal Cancer Cells



    • NUC-7738 Demonstrates Anti-Cancer Activity, Prolonged Stable Disease and a Favorable Tolerability Profile in Patients with Advanced Solid Tumors



    • NUC-7738 Generates High and Prolonged Intracellular Levels of the Active Anti-Cancer Metabolite 3'-dATP



    • Acelarin Induces Persistent DNA Damage in Biliary Tract Cancer Cells

    EDINBURGH, United Kingdom, April 10, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced the presentation of five posters at the American Association for Cancer Research (AACR) Annual Meeting 2021 being held virtually April 9 to 14, 2021. Data from all three of NuCana's ProTides in clinical development were presented. Summaries of the posters are described below.



    NUC-3373

    NuCana presented two posters on NUC-3373, its ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil (5-FU), a very widely used anti-cancer drug. NUC-3373 has been designed to overcome the main challenges associated with 5-FU and capecitabine, including cancer-resistance mechanisms, the generation of toxic metabolites and unfavorable pharmacokinetic profile.

    Poster Title: NUC-3373, a targeted inhibitor of thymidylate synthase, in patients with advanced colorectal cancer

    This poster describes further encouraging interim data from 38 patients with metastatic colorectal cancer. In this difficult-to-treat group, who had received a median of four prior lines of therapy, NUC-3373, with or without leucovorin, demonstrated a 62% disease control rate (defined as stable disease lasting more than 8 weeks) in the efficacy-evaluable population. Three patients experienced reductions in their target lesions of 40%, 28% and 15% and several patients achieved a longer progression-free survival on NUC-3373 than they had on their prior therapy. NUC-3373 also continues to demonstrate a favorable safety profile with no FBAL or FUTP-associated Grade 3 or 4 toxicities, such as hand-foot syndrome, GI or hematological adverse events.

    Poster Title: NUC-3373-induced DAMPs release in CRC cells promotes natural killer cell activation

    The second NUC-3373 poster showed that NUC-3373-treated colon cancer cells are able to activate a natural killer (NK) cell response. NUC-3373 was shown to induce the release of damage associated molecular patterns (DAMPs) which may restore NK cell-mediated immune responses by reducing inhibitory signals. Thus, NUC-3373 has the potential to evoke immunogenic cell death and may enhance the clinical utility of immunotherapy agents.

    NUC-7738

    NuCana presented two posters on NUC-7738, a ProTide transformation of a novel nucleoside analog, 3'-deoxyadenosine or 3'-dA. NUC-7738, which has several potential anti-cancer mechanisms of action, is being evaluated in a Phase I study in patients with advanced solid tumors who have exhausted all standard therapies.

    Poster Title: NUC-7738, a novel ProTide transformation of 3'-deoxyadenosine, in patients with advanced solid tumors

    The first poster describes additional interim data from the ongoing Phase I study. These data demonstrate NUC-7738's encouraging anti-cancer activity and favorable tolerability profile. Three case studies were described detailing patients who achieved tumor reductions and prolonged stable disease on NUC-7738.

    Poster Title: From bench to bedside: Using ProTide chemistry to transform 3'-deoxyadenosine into the novel anti-cancer agent NUC-7738

    The second poster describes how NUC-7738 was designed to overcome the key cancer resistance mechanisms which have prevented the clinical development of 3'-dA. NUC-7738 was shown to efficiently generate high and prolonged intracellular levels of the active anti-cancer metabolite, 3'-dATP, and to cause cell death by activation of apoptotic pathways, as well as through inhibition of NFkB nuclear translocation.

    Acelarin

    Poster Title: NUC-1031 causes incorporation of fluorinated deoxycytidine into DNA, inducing persistent damage in biliary tract cancer cells

    NuCana presented a poster that further demonstrated Acelarin's activity in biliary tract cancer cells. Specifically, the poster described how Acelarin (NUC-1031) is converted to the active anti-cancer metabolite (dFdCTP) and demonstrated that it is incorporated into DNA, inducing persistent double-strand breaks. This leads to cell cycle arrest and DNA damage resulting in apoptosis in biliary tract cancer cells.

    Abstracts and full session details can be found at www.aacr.org

    About NuCana

    NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. NuCana's robust pipeline includes three ProTides in clinical development. Acelarin and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents. Acelarin is in a Phase III study for patients with advanced biliary tract cancer and a Phase III study for patients with metastatic pancreatic cancer for which enrollment has been suspended. NUC-3373 is in a Phase I study for the potential treatment of a wide range of patients with advanced solid tumors and a Phase Ib study for patients with metastatic colorectal cancer. Our third ProTide, NUC-7738, is a transformation of a novel nucleoside analog (3'-deoxyadenosine) and is in a Phase I study for patients with advanced solid tumors.

    Forward-Looking Statements

    This press release may contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the "Company"). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning the Company's planned and ongoing clinical studies for the Company's product candidates and the potential advantages of those product candidates, including Acelarin, NUC-3373 and NUC-7738; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies; the Company's goals with respect to the development, regulatory pathway and potential use, if approved, of each of its product candidates; and the utility of prior non-clinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of the Company's Annual Report on Form 20-F for the year ended December 31, 2020 filed with the Securities and Exchange Commission ("SEC") on March 4, 2021, and subsequent reports that the Company files with the SEC. Forward-looking statements represent the Company's beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward-looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.

    For more information, please contact:

    NuCana plc

    Hugh S. Griffith

    Chief Executive Officer

    T: +44 131 357 1111

    E:  

    Westwicke, an ICR Company

    Chris Brinzey

    T: +1 339-970-2843

    E:  

    RooneyPartners

    Marion Janic

    T: +1 212-223-4017

    E:  



    View Full Article Hide Full Article
  4. Presented Encouraging Clinical Data for NUC-3373 and NUC-7738

    Continued to Enroll Global Phase III Biliary Tract Cancer Study (NuTide:121) of Acelarin with Potential for Accelerated Approval Filing

    Raised $80 million in a Follow-on Offering

    Augmented the Board of Directors with Two Key Appointments

    Numerous Clinical Data Announcements and Study Initiations Expected in 2021

    EDINBURGH, United Kingdom, March 04, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced financial results for the fourth quarter and year ended December 31, 2020 and provided an update on its broad clinical program with its transformative ProTide therapeutics.

    As of December 31, 2020, NuCana had cash and cash equivalents of £87.4 million compared to £100.7…

    Presented Encouraging Clinical Data for NUC-3373 and NUC-7738

    Continued to Enroll Global Phase III Biliary Tract Cancer Study (NuTide:121) of Acelarin with Potential for Accelerated Approval Filing

    Raised $80 million in a Follow-on Offering

    Augmented the Board of Directors with Two Key Appointments

    Numerous Clinical Data Announcements and Study Initiations Expected in 2021

    EDINBURGH, United Kingdom, March 04, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced financial results for the fourth quarter and year ended December 31, 2020 and provided an update on its broad clinical program with its transformative ProTide therapeutics.

    As of December 31, 2020, NuCana had cash and cash equivalents of £87.4 million compared to £100.7 million at September 30, 2020 and £52.0 million at December 31, 2019. NuCana continues to advance its various clinical programs and reported a net loss of £12.3 million for the quarter ended December 31, 2020, as compared to £7.7 million for the quarter ended December 31, 2019. Net loss for the year ended December 31, 2020 was £30.7 million, compared to a net loss of £21.4 million for the year ended December 31, 2019. Basic and diluted loss per share was £0.24 for the quarter and £0.81 for the year ended December 31, 2020, as compared to £0.24 per share for the comparable quarter and £0.66 for the year ended December 31, 2019.

    "2020 was a very successful year for NuCana," said Hugh S. Griffith, NuCana's Founder and Chief Executive Officer. "Against the challenging backdrop of the COVID-19 pandemic, we continued to advance all of our clinical programs and generate encouraging clinical and non-clinical data. Throughout 2020, we made good progress in the Phase III NuTide:121 biliary tract cancer study and expect to enroll sufficient patients in 2021 to complete the first interim analysis in 2022, which may support an accelerated approval filing. In September, we provided an update on two of our lead programs at ESMO that further validate the use of our proprietary ProTide technology. NUC-3373 continued to demonstrate its potential to offer enhanced efficacy, an improved safety profile and a more convenient dosing regimen as compared to 5-FU in patients with colorectal cancer. We also announced the first-ever clinical data for NUC-7738, which showed promising indications of anti-cancer activity and a favorable tolerability profile."

    Mr. Griffith continued: "During 2020, we completed a successful $80 million follow-on offering that significantly strengthens our balance sheet. We also appointed a new non-executive Chairman, Andrew Kay and a new non-executive director, Bali Muralidhar. Both individuals bring a wealth of experience and we look forward to their contributions as we advance NuCana's programs."

    Mr. Griffith concluded: "We were excited to begin 2021 with the announcement of additional interim data for NUC-3373 in patients with colorectal cancer that continued to demonstrate encouraging efficacy and safety at ASCO GI. We look forward to continuing to drive recruitment across all of our ongoing studies, announce additional clinical data, and initiate new studies in 2021. We remain focused on our mission of significantly improving treatment outcomes for patients with cancer."

    Anticipated 2021 Milestones

    • Acelarin is a ProTide transformation of gemcitabine. In 2021, NuCana expects to:



      • Complete recruitment sufficient to enable the first interim analysis in 2022 of the Phase III study of Acelarin combined with cisplatin as a first-line treatment for patients with advanced biliary tract cancer.



    • NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-FU. In 2021, NuCana expects to:



      • Report data from the Phase Ib study (NuTide:302) of NUC-3373 in combination with other agents with which 5-FU is typically combined, such as leucovorin, oxaliplatin and irinotecan in patients with advanced colorectal cancer.

      • Initiate and report data from a Phase Ib expansion / Phase II study of NUC-3373 in combination with other agents for patients with colorectal cancer.
      • Initiate a Phase III study of NUC-3373 in combination with other agents for patients with colorectal cancer.
      • Report data from the Phase I study (NuTide:301) of NUC-3373 in patients with advanced solid tumors.
    • NUC-7738 is a ProTide transformation of a novel nucleoside analog, 3'-deoxyadenosine. In 2021, NuCana expects to:



      • Report data from the Phase I study (NuTide:701) of NUC-7738 in patients with advanced solid tumors.

      • Initiate a Phase II study of NUC-7738 in patients with solid tumors.

    About NuCana

    NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. NuCana's robust pipeline includes three ProTides in clinical development. Acelarin and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents. Acelarin is in a Phase III study for patients with advanced biliary tract cancer and a Phase III study for patients with metastatic pancreatic cancer for which enrollment has been suspended. NUC-3373 is in a Phase I study for the potential treatment of a wide range of patients with advanced solid tumors and a Phase Ib study for patients with metastatic colorectal cancer. Our third ProTide, NUC-7738, is a transformation of a novel nucleoside analog (3'-deoxyadenosine) and is in a Phase I study for patients with advanced solid tumors.

    Forward-Looking Statements

    This press release may contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the "Company"). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning the Company's planned and ongoing clinical studies for the Company's product candidates and the potential advantages of those product candidates, including Acelarin, NUC-3373 and NUC-7738; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies; the Company's goals with respect to the development, regulatory pathway and potential use, if approved, of each of its product candidates; and the utility of prior non-clinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of the Company's Annual Report on Form 20-F for the year ended December 31, 2020 to be filed with the Securities and Exchange Commission ("SEC") on March 4, 2021, and subsequent reports that the Company files with the SEC. Forward-looking statements represent the Company's beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward-looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.





    Condensed Consolidated Statements of Operations

      For the three months ended

    December 31,
      For the year ended

    December 31,
     
      2020  2019  2020  2019 
      (in thousands, except per share data) 
       (unaudited)  
      £  £  £  £ 
                     
    Research and development expenses  (7,981)  (5,177)  (25,899)  (19,728)
    Administrative expenses  (1,906)  (1,722)  (7,050)  (5,953)
    Net foreign exchange losses  (4,082)  (2,210)  (3,472)  (1,019)
    Operating loss  (13,969)  (9,109)  (36,421)  (26,700)
    Finance income  12   182   246   1,049 
    Loss before tax  (13,957)  (8,927)  (36,175)  (25,651)
    Income tax credit  1,696   1,219   5,493   4,239 
    Loss for the period  (12,261)  (7,708)  (30,682)  (21,412)
                     
                     
    Basic and diluted loss per share  (0.24)  (0.24)  (0.81)  (0.66)





    Condensed Consolidated Statements of Financial Position

    at December 31,

      2020  2019 
      (in thousands) 
      £  £ 
    Assets        
    Non-current assets        
    Intangible assets  4,753   3,960 
    Property, plant and equipment  1,189   1,109 
    Deferred tax asset  44   46 
       5,986   5,115 
             
    Current assets        
    Prepayments, accrued income and other receivables  4,628   4,710 
    Current income tax receivable  9,822   8,481 
    Cash and cash equivalents  87,356   51,962 
       101,806   65,153 
             
    Total assets  107,792   70,268 
             
    Equity and liabilities        
    Capital and reserves        
    Share capital and share premium  142,937   80,840 
    Other reserves  66,887   62,737 
    Accumulated deficit  (110,594)  (80,055)
    Total equity attributable to equity holders of the Company  99,230   63,522 
             
    Non-current liabilities        
    Provisions  46   26 
    Lease liabilities  367   538 
       413   564 
             
    Current liabilities        
    Trade payables  2,257   2,412 
    Payroll taxes and social security  177   160 
    Accrued expenditure  5,437   3,342 
    Lease liabilities  278   268 
       8,149   6,182 
             
    Total liabilities  8,562   6,746 
             
    Total equity and liabilities  107,792   70,268 





    Condensed Consolidated Statements of Cash Flows

    for the year ended December 31,

      2020  2019 
      (in thousands) 
      £  £ 
    Cash flows from operating activities        
    Loss for the year  (30,682)  (21,412)
    Adjustments for:        
    Income tax credit  (5,493)  (4,239)
    Amortization and depreciation  890   718 
    Finance income  (246)  (1,049)
    Interest expense on lease liabilities  26   - 
    Share-based payments  4,305   3,226 
    Net foreign exchange losses  3,481   1,006 
       (27,719)  (21,750)
    Movements in working capital:        
    Increase in prepayments accrued income and other receivables  (9)  (2,452)
    Decrease in trade payables  (155)  (43)
    Increase in payroll taxes, social security and accrued expenditure  2,112   393 
    Movements in working capital  1,948   (2,102
    Cash used in operations  (25,771)  (23,852)
    Net income tax received  4,152   19 
    Net cash used in operating activities  (21,619)  (23,833)
    Cash flows from investing activities        
    Interest received  319   1,116 
    Payments for property, plant and equipment  (361)  (46)
    Payments for intangible assets  (1,271)  (1,215)
    Net cash used in investing activities  (1,313)  (145)
    Cash flows from financing activities        
    Payments of lease liabilities  (297)  (197)
    Proceeds from lease incentives received  -   25 
    Proceeds from issue of share capital – exercise of share options  15   125 
    Proceeds from issue of share capital  66,581   - 
    Share issue expenses  (4,499  - 
    Net cash from (used in) financing activities  61,800   (47)
    Net increase (decrease) in cash and cash equivalents  38,868   (24,025)
    Cash and cash equivalents at beginning of year  51,962   76,972 
    Effect of exchange rate changes on cash and cash equivalents  (3,474)  (985)
    Cash and cash equivalents at end of year  87,356   51,962 
             



    For more information, please contact:

    NuCana plc

    Hugh S. Griffith

    Chief Executive Officer

    T: +44 131 357 1111

    E:

    Westwicke, an ICR Company

    Chris Brinzey

    T: +1 339-970-2843

    E:

    RooneyPartners

    Marion Janic

    T: +1 212-223-4017

    E:



    View Full Article Hide Full Article
View All NuCana plc News